February 1, 2019 / 10:24 PM / 6 months ago

Mylan loses challenge to UCB epilepsy drug at Fed Circuit

A federal appeals court on Friday upheld a U.S. patent on Belgian pharmaceutical company UCB Inc’s epilepsy drug Vimpat, dealing a blow to plans by Mylan NV and other generic drug companies to introduce lower-cost versions.

The U.S. Court of Appeals for the Federal Circuit affirmed a determination by the Patent Trial and Appeal Board that the generic drug companies failed to prove the patent was invalid on obviousness grounds.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2Be9CAP

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below